Fulcrum Therapeutics (FULC) Free Cash Flow (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Free Cash Flow data on file, last reported at -$18.8 million in Q1 2026.

• On a quarterly basis, Free Cash Flow fell 22.95% year-over-year to -$18.8 million in Q1 2026; TTM through Mar 2026 was -$63.9 million, a 945.09% decrease from a year earlier, with the FY2025 full-year figure at -$60.4 million, down 2319.03% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$18.8 million, down from -$17.0 million in the prior quarter.
• Over the last five years, Free Cash Flow for FULC reached as high as $58.9 million in Q2 2024 and fell as low as -$27.8 million in Q3 2022.
• Historically, Free Cash Flow has averaged -$15.9 million across 5 years, with a median of -$19.7 million in 2022.
• Across the five-year window, Free Cash Flow surged 385.12% in 2024 and plunged 123.46% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$19.7 million in 2022, then declined by 20.12% to -$23.7 million in 2023, then grew by 28.2% to -$17.0 million in 2024, then advanced by 0.21% to -$17.0 million in 2025, then decreased by 10.62% to -$18.8 million in 2026.
• Per Business Quant data, the three most recent Free Cash Flow figures were -$18.8 million in Q1 2026, -$17.0 million in Q4 2025, and -$14.3 million in Q3 2025.